Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018160067) SPECIFIC INCREASE OF DOPAMINE SYNTHESIS THROUGH TARGETING OF THE GUANYLATE CYCLASE 2C RECEPTOR IN THE TREATMENT OF PARKINSON'S DISEASE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/160067 International Application No.: PCT/NL2018/050133
Publication Date: 07.09.2018 International Filing Date: 02.03.2018
IPC:
A61K 38/10 (2006.01) ,A61K 45/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10
Peptides having 12 to 20 amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants:
UNIVERSITEIT VAN AMSTERDAM [NL/NL]; Spui 21 1012 WX Amsterdam, NL
Inventors:
VAN DER HEIDE, Lars Philip; NL
Agent:
JANSEN, CM.; V.O. Carnegieplein 5 2517 KJ Den Haag, NL
Priority Data:
17158996.302.03.2017EP
Title (EN) SPECIFIC INCREASE OF DOPAMINE SYNTHESIS THROUGH TARGETING OF THE GUANYLATE CYCLASE 2C RECEPTOR IN THE TREATMENT OF PARKINSON'S DISEASE
(FR) AUGMENTATION SPÉCIFIQUE DE LA SYNTHÈSE DE LA DOPAMINE PAR CIBLAGE DU RÉCEPTEUR DE LA GUANYLATE CYCLASE 2C DANS LE TRAITEMENT DE LA MALADIE DE PARKINSON
Abstract:
(EN) In embodiments the invention relates to means and methods for the treatment of Parkinson's disease. In some embodiments the means and methods involve a GUCY2C agonist. The invention also relates to test systems and cells that are suited to identify new candidate compounds for the treatment of Parkinson's disease.
(FR) Dans des modes de réalisation, l'invention concerne des moyens et des méthodes de traitement de la maladie de Parkinson. Dans certains modes de réalisation, les moyens et les méthodes impliquent un agoniste de GUCY2C. L'invention concerne également des systèmes et des cellules d'essai qui sont appropriés pour identifier de nouveaux composés candidats pour le traitement de la maladie de Parkinson.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)